Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin): An example of potential problems for extrapolation of active drug concentrations from in vitro studies

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 1, 2004, Pages 89-90

  Tognon, Gianluca ^a   Frapolli, Roberta ^a   Zaffaroni, Marco ^a   Erba, Eugenio ^a   Zucchetti, Massimo ^a   Faircloth, Glynn T ^b   D'Incalci, Maurizio ^a  

^a Ist Ric Farmacologiche Mario Negri ^*  (Italy)

^b PharmaMar USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; HUMAN SERUM ALBUMIN; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CLINICAL TRIAL; CYTOTOXICITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; IC 50; OVARY CANCER; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CATTLE; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA; DIOXOLES; FEMALE; HUMANS; ISOQUINOLINES; OVARIAN NEOPLASMS; SERUM; TETRAHYDROISOQUINOLINES;

EID: 0742304111     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0704-y     Document Type: Article

References (8)

1. Boyd MR, Paull KD (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91-109
2. Delaloge S, Yovine A, Taamma A, et al (2001) Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients: preliminary evidence of activity. J Clin Oncol 19:1248-1255
3. Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG (2002) Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcoma: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50:309-319
4. Rosing H, Hillebrand MJX, Jimeno JM, Gòmez A, Floriano P, Faircloth G, Henrar REC, Vermorken JB, Cvitkovic E, Bult A, Beijnen JH (1998) Quantitative determination of ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 33:1134-1140
5. Ryan DP, Supko JG, Eder JP, et al (2001) Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 7:231-242
6. Taamma A, Misset JL, Riofrio M, et al (2001) Phase I and pharmacokinetic study of ecteinascidin 743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 19:1256-1265
7. van Kesteren C, Cvitkovic E, Taamma A, et al (2000) Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 6:4725-4732
8. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, et al (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349